Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Express Scripts
Baxter
Merck
Moodys

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR AZACITIDINE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Azacitidine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004062 ↗ Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer Completed National Cancer Institute (NCI) Phase 1 1999-07-01 RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine. PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer.
NCT00004062 ↗ Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer Completed Lucille P. Markey Cancer Center at University of Kentucky Phase 1 1999-07-01 RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine. PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer.
NCT00004871 ↗ Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed National Cancer Institute (NCI) Phase 1 2000-05-01 RATIONALE: Azacitidine plus phenylbutyrate may help leukemia cells develop into normal white blood cells. PURPOSE: Phase I trial to study the effectiveness of combining azacitidine and phenylbutyrate in treating patients who have acute myeloid leukemia or myelodysplastic syndrome.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Azacitidine

Condition Name

Condition Name for Azacitidine
Intervention Trials
Acute Myeloid Leukemia 120
Myelodysplastic Syndromes 89
Myelodysplastic Syndrome 80
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Azacitidine
Intervention Trials
Leukemia 270
Myelodysplastic Syndromes 257
Leukemia, Myeloid, Acute 251
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Azacitidine

Trials by Country

Trials by Country for Azacitidine
Location Trials
Japan 204
China 167
France 156
Canada 146
Germany 141
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Azacitidine
Location Trials
Texas 181
New York 122
California 121
Illinois 87
Florida 81
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Azacitidine

Clinical Trial Phase

Clinical Trial Phase for Azacitidine
Clinical Trial Phase Trials
Phase 4 3
Phase 3 55
Phase 2/Phase 3 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Azacitidine
Clinical Trial Phase Trials
Completed 163
Recruiting 132
Active, not recruiting 72
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Azacitidine

Sponsor Name

Sponsor Name for Azacitidine
Sponsor Trials
National Cancer Institute (NCI) 91
Celgene Corporation 78
Celgene 60
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Azacitidine
Sponsor Trials
Industry 442
Other 401
NIH 93
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
McKinsey
Johnson and Johnson
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.